Morris RT - Search Results

1

Expression of GLUT-1 in epithelial ovarian carcinoma: correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction.

Semaan A, Munkarah AR, Arabi H, Bandyopadhyay S, Seward S, Kumar S, Qazi A, Hussein Y, Morris RT, Ali-Fehmi R. Semaan A, et al. Among authors: morris rt. Gynecol Oncol. 2011 Apr;121(1):181-6. doi: 10.1016/j.ygyno.2010.11.019. Epub 2010 Dec 16. Gynecol Oncol. 2011. PMID: 21167567

2

Organotypic culture of human ovarian surface epithelial cells: a potential model for ovarian carcinogenesis.

Gregoire L, Munkarah A, Rabah R, Morris RT, Lancaster WD. Gregoire L, et al. Among authors: morris rt. In Vitro Cell Dev Biol Anim. 1998 Sep;34(8):636-9. doi: 10.1007/s11626-996-0012-z. In Vitro Cell Dev Biol Anim. 1998. PMID: 9769148

3

Immature teratomas of the genital tract in older women.

Doss BJ, Jacques SM, Qureshi F, Chang CH, Christensen CW, Morris RT, Lawrence WD. Doss BJ, et al. Among authors: morris rt. Gynecol Oncol. 1999 Jun;73(3):433-8. doi: 10.1006/gyno.1999.5345. Gynecol Oncol. 1999. PMID: 10366474

4

Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer.

Munkarah A, Levenback C, Wolf JK, Bodurka-Bevers D, Tortolero-Luna G, Morris RT, Gershenson DM. Munkarah A, et al. Among authors: morris rt. Gynecol Oncol. 2001 May;81(2):237-41. doi: 10.1006/gyno.2001.6143. Gynecol Oncol. 2001. PMID: 11330956

5

Effects of prostaglandin E(2) on proliferation and apoptosis of epithelial ovarian cancer cells.

Munkarah AR, Morris R, Baumann P, Deppe G, Malone J, Diamond MP, Saed GM. Munkarah AR, et al. J Soc Gynecol Investig. 2002 May-Jun;9(3):168-73. J Soc Gynecol Investig. 2002. PMID: 12009392

6

Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer.

Morris R, Munkarah A. Morris R, et al. Oncologist. 2002;7 Suppl 5:29-35. doi: 10.1634/theoncologist.7-suppl_5-29. Oncologist. 2002. PMID: 12324631 Free article. Review.

7

Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells.

Munkarah AR, Genhai Z, Morris R, Baker VV, Deppe G, Diamond MP, Saed GM. Munkarah AR, et al. Gynecol Oncol. 2003 Mar;88(3):429-33. doi: 10.1016/s0090-8258(03)00084-2. Gynecol Oncol. 2003. PMID: 12648598

8

Upper extremity deep vein thrombosis associated with indwelling peripheral venous catheters in gynecology oncology patients.

Schimp VL, Munkarah AR, Morris RT, Deppe G, Malone J Jr. Schimp VL, et al. Among authors: morris rt. Gynecol Oncol. 2003 May;89(2):301-5. doi: 10.1016/s0090-8258(03)00074-x. Gynecol Oncol. 2003. PMID: 12713995

9

Weekly topotecan in the management of ovarian cancer.

Morris RT. Morris RT. Gynecol Oncol. 2003 Sep;90(3 Pt 2):S34-8. doi: 10.1016/s0090-8258(03)00470-0. Gynecol Oncol. 2003. PMID: 13129494 Review.

10

The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma.

Ali-Fehmi R, Che M, Khalifeh I, Malone JM, Morris R, Lawrence WD, Munkarah AR. Ali-Fehmi R, et al. Cancer. 2003 Oct 1;98(7):1423-9. doi: 10.1002/cncr.11650. Cancer. 2003. PMID: 14508829 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

196 results

Search Page

Filters